CN1279980C - 一种抗实体肿瘤药物组合物 - Google Patents
一种抗实体肿瘤药物组合物 Download PDFInfo
- Publication number
- CN1279980C CN1279980C CN 200410035924 CN200410035924A CN1279980C CN 1279980 C CN1279980 C CN 1279980C CN 200410035924 CN200410035924 CN 200410035924 CN 200410035924 A CN200410035924 A CN 200410035924A CN 1279980 C CN1279980 C CN 1279980C
- Authority
- CN
- China
- Prior art keywords
- tumor
- entity
- hydroxylamine
- medicine composition
- methoxamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 136
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 125
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 claims abstract description 72
- 229960005192 methoxamine Drugs 0.000 claims abstract description 72
- 229940079593 drug Drugs 0.000 claims abstract description 70
- 238000011282 treatment Methods 0.000 claims abstract description 24
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims description 56
- 238000011275 oncology therapy Methods 0.000 claims description 55
- 239000003112 inhibitor Substances 0.000 claims description 47
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 32
- 229960001052 streptozocin Drugs 0.000 claims description 32
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 32
- YJZJEQBSODVMTH-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2-hydroxyethyl)-1-nitrosourea Chemical compound OCCNC(=O)N(N=O)CCCl YJZJEQBSODVMTH-UHFFFAOYSA-N 0.000 claims description 30
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 30
- 229960004964 temozolomide Drugs 0.000 claims description 30
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 28
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 27
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 24
- 229960003440 semustine Drugs 0.000 claims description 24
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 claims description 23
- 229920001577 copolymer Polymers 0.000 claims description 20
- 229950003860 elmustine Drugs 0.000 claims description 20
- HYHJFNXFVPGMBI-UHFFFAOYSA-N 2-[[2-chloroethyl(nitroso)carbamoyl]-methylamino]acetamide Chemical compound NC(=O)CN(C)C(=O)N(CCCl)N=O HYHJFNXFVPGMBI-UHFFFAOYSA-N 0.000 claims description 19
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 17
- 229960001842 estramustine Drugs 0.000 claims description 17
- XWPCYYOZOJKYKQ-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-[2-[[2-chloroethyl(nitroso)carbamoyl]amino]ethyldisulfanyl]ethyl]-1-nitrosourea Chemical compound ClCCN(N=O)C(=O)NCCSSCCNC(=O)N(N=O)CCCl XWPCYYOZOJKYKQ-UHFFFAOYSA-N 0.000 claims description 16
- -1 O-hydroxylamine Chemical compound 0.000 claims description 16
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 15
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 claims description 15
- 229950006933 atrimustine Drugs 0.000 claims description 15
- 241000196324 Embryophyta Species 0.000 claims description 14
- 230000001093 anti-cancer Effects 0.000 claims description 14
- 229960002247 lomustine Drugs 0.000 claims description 14
- 229960001420 nimustine Drugs 0.000 claims description 14
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims description 14
- 239000004626 polylactic acid Substances 0.000 claims description 14
- 229960005243 carmustine Drugs 0.000 claims description 13
- ZLWYEPMDOUQDBW-UHFFFAOYSA-N 6-aminonicotinamide Chemical compound NC(=O)C1=CC=C(N)N=C1 ZLWYEPMDOUQDBW-UHFFFAOYSA-N 0.000 claims description 12
- UOAFGUOASVSLPK-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2,2-dimethylpropyl)-1-nitrosourea Chemical compound CC(C)(C)CNC(=O)N(N=O)CCCl UOAFGUOASVSLPK-UHFFFAOYSA-N 0.000 claims description 11
- YQYBWJPESSJLTK-HXFLIBJXSA-N 1-(2-chloroethyl)-3-[(2r,3s,4r,6s)-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]-1-nitrosourea Chemical compound CO[C@@H]1C[C@@H](NC(=O)N(CCCl)N=O)[C@H](O)[C@@H](CO)O1 YQYBWJPESSJLTK-HXFLIBJXSA-N 0.000 claims description 10
- YASNUXZKZNVXIS-CBNXCZCTSA-N [(3ar,6r,6ar)-4-[[2-chloroethyl(nitroso)carbamoyl]amino]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl 4-nitrobenzoate Chemical compound C([C@@H]1[C@H]2OC(O[C@H]2C(NC(=O)N(CCCl)N=O)O1)(C)C)OC(=O)C1=CC=C([N+]([O-])=O)C=C1 YASNUXZKZNVXIS-CBNXCZCTSA-N 0.000 claims description 10
- NRUFLTXGIPFVSH-KBVRNWHJSA-N [(8r,9s,13s,14s,17s)-3-[bis(2-chloroethyl)carbamoyloxy]-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] (2s)-2-aminopropanoate Chemical compound C1CC2=CC(OC(=O)N(CCCl)CCCl)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)[C@@H](N)C)[C@@]1(C)CC2 NRUFLTXGIPFVSH-KBVRNWHJSA-N 0.000 claims description 10
- 229950009009 alestramustine Drugs 0.000 claims description 10
- 229950010949 ambamustine Drugs 0.000 claims description 10
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 10
- 229960002707 bendamustine Drugs 0.000 claims description 10
- 229950003042 bofumustine Drugs 0.000 claims description 10
- 229950011425 ditiomustine Drugs 0.000 claims description 10
- 229950005678 ecomustine Drugs 0.000 claims description 10
- XPGDODOEEWLHOI-GSDHBNRESA-N ethyl (2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-fluorophenyl)propanoyl]amino]-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(F)=CC=1)C1=CC=CC(N(CCCl)CCCl)=C1 XPGDODOEEWLHOI-GSDHBNRESA-N 0.000 claims description 10
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 claims description 10
- 229960004783 fotemustine Drugs 0.000 claims description 10
- QXYYYPFGTSJXNS-UHFFFAOYSA-N mitozolomide Chemical compound N1=NN(CCCl)C(=O)N2C1=C(C(=O)N)N=C2 QXYYYPFGTSJXNS-UHFFFAOYSA-N 0.000 claims description 10
- COKGUJJIBXWRNV-CYNREMDZSA-N (3r,4s,5r,6r)-6-[bis(2-chloroethyl)aminomethyl]oxane-2,3,4,5-tetrol Chemical compound OC1O[C@H](CN(CCCl)CCCl)[C@H](O)[C@H](O)[C@H]1O COKGUJJIBXWRNV-CYNREMDZSA-N 0.000 claims description 9
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 claims description 9
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 9
- 229950009403 galamustine Drugs 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 9
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 9
- 229960001055 uracil mustard Drugs 0.000 claims description 9
- RCLLNBVPCJDIPX-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCNC(=O)N(N=O)CCCl RCLLNBVPCJDIPX-UHFFFAOYSA-N 0.000 claims description 8
- OFJWFSNDPCAWDK-UHFFFAOYSA-N 2-phenylbutyric acid Chemical compound CCC(C(O)=O)C1=CC=CC=C1 OFJWFSNDPCAWDK-UHFFFAOYSA-N 0.000 claims description 8
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 claims description 8
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 claims description 8
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 8
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 claims description 8
- 229950008612 mannomustine Drugs 0.000 claims description 8
- 229960004023 minocycline Drugs 0.000 claims description 8
- ARKYUICTMUZVEW-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3C=CC(=CC=3)N(CCCl)CCCl)C=2)C)=CN1C ARKYUICTMUZVEW-UHFFFAOYSA-N 0.000 claims description 8
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 8
- 229960004694 prednimustine Drugs 0.000 claims description 8
- 229960002185 ranimustine Drugs 0.000 claims description 8
- 229950006050 spiromustine Drugs 0.000 claims description 8
- 229950005667 tallimustine Drugs 0.000 claims description 8
- 108010021891 tallimustine Proteins 0.000 claims description 8
- 229950010168 tauromustine Drugs 0.000 claims description 8
- VEKMHZIDYGAWJW-UHFFFAOYSA-N C(CCC)NO.[O] Chemical compound C(CCC)NO.[O] VEKMHZIDYGAWJW-UHFFFAOYSA-N 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 210000001685 thyroid gland Anatomy 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 201000000274 Carcinosarcoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 210000004696 endometrium Anatomy 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000005075 mammary gland Anatomy 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims 1
- 210000001989 nasopharynx Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 29
- 238000000034 method Methods 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 16
- 229920000642 polymer Polymers 0.000 abstract description 13
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 7
- 238000001959 radiotherapy Methods 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 230000033616 DNA repair Effects 0.000 abstract description 2
- 102000011724 DNA Repair Enzymes Human genes 0.000 abstract 4
- 108010076525 DNA Repair Enzymes Proteins 0.000 abstract 4
- 239000002532 enzyme inhibitor Substances 0.000 abstract 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract 3
- WVAKABMNNSMCDK-UHFFFAOYSA-N sulfacarbamide Chemical compound NC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 WVAKABMNNSMCDK-UHFFFAOYSA-N 0.000 abstract 3
- 229950010053 sulfacarbamide Drugs 0.000 abstract 3
- 231100000057 systemic toxicity Toxicity 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 206010006187 Breast cancer Diseases 0.000 description 12
- 208000026310 Breast neoplasm Diseases 0.000 description 12
- 201000008275 breast carcinoma Diseases 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 102100021906 Cyclin-O Human genes 0.000 description 10
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 10
- KPMKNHGAPDCYLP-UHFFFAOYSA-N nimustine hydrochloride Chemical compound Cl.CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 KPMKNHGAPDCYLP-UHFFFAOYSA-N 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 9
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 8
- 229920002732 Polyanhydride Polymers 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000654 additive Substances 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 5
- 229920000954 Polyglycolide Polymers 0.000 description 5
- GKFKUZBTGYKBFS-XIHUBIEQSA-N [(2r,3s,4r,5r)-3,4,6-triacetyloxy-5-[[2-chloroethyl(nitroso)carbamoyl]amino]oxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1OC(OC(C)=O)[C@H](NC(=O)N(CCCl)N=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O GKFKUZBTGYKBFS-XIHUBIEQSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 239000004633 polyglycolic acid Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 208000018084 Bone neoplasm Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229920005576 aliphatic polyanhydride Polymers 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 229920002627 poly(phosphazenes) Polymers 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 229920001273 Polyhydroxy acid Polymers 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 2
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960001668 cefuroxime Drugs 0.000 description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000011254 conventional chemotherapy Methods 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 239000003107 drug analog Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 150000002443 hydroxylamines Chemical class 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229950004403 polifeprosan Drugs 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- FVLVBPDQNARYJU-UHFFFAOYSA-N semustine Chemical compound CC1CCC(NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- IGMMTYZWNUSEEU-UHFFFAOYSA-N 3-(2-chloroethyl)-1-cyclohexyl-1-nitrosourea Chemical compound ClCCNC(=O)N(N=O)C1CCCCC1 IGMMTYZWNUSEEU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000002653 magnetic therapy Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000003697 methyltransferase inhibitor Substances 0.000 description 1
- 229950005967 mitozolomide Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 229950010681 neptamustine Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- UVTPMAJGFRLLKF-UHFFFAOYSA-N o-(4-aminooxybutyl)hydroxylamine Chemical compound NOCCCCON UVTPMAJGFRLLKF-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229920001558 organosilicon polymer Polymers 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003361 porogen Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940116353 sebacic acid Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
瘤细胞 | MX | BCNU | MX+BCNU | ACNU | MX+ACNU | CCNU | MX+CCNU | GCNU | MX+GCNU |
CNSC6SABCBALHPAT | 68625854546054 | 64646064625856 | 90968694989094 | 66605654626266 | 98989284829298 | 64646054526866 | 90968694989094 | 66606664626066 | 98989284829298 |
瘤细胞 | MA | Al | MA+Al | At | MA+At | Am | MA+Am | Be | MA+Be |
CNSC6SABCBALHPAT | 67%62%56%54%57%62%54% | 64%66%60%56%52%66%66% | 92%96%88%94%96%90%96% | 67%60%58%54%62%68%66% | 96%98%90%84%80%90%98% | 65%64%68%64%68%50%56% | 94%96%86%90%98%92%94% | 54%50%58%54%56%50%56% | 96%94%92%86%82%90%98% |
瘤细胞 | HX | Di | HX+Di | Bo | HX+Bo | El | HX+El | Ec | HX+Ec |
CNSC6SABCBALHPAT | 67%62%56%54%57%62%54% | 64%66%60%56%52%66%66% | 92%96%88%94%96%90%96% | 67%60%58%54%62%68%66% | 96%98%90%84%80%90%98% | 65%64%68%64%68%50%56% | 94%96%96%0%98%92%94% | 64%60%58%64%66%60%66% | 96%94%92%86%82%90%98% |
瘤细胞 | MC | Fo | MC+Fo | Es | MC+Es | He | MC+He | Ne | MC+Ne |
CNSC6SABCBALHPAT | 57%52%46%58%57%60%55% | 68%76%60%66%58%68%66% | 98%96%88%94%96%98%96% | 68%62%58%54%68%68%68% | 98%98%90%84%88%90%98% | 68%64%68%60%68%50%58% | 88%86%96%86%88%96%94% | 64%60%48%54%76%70%66% | 94%90%95%88%82%92%96% |
瘤细胞 | MX | STZ | MX+STZ | BCNU | MX+BCNU | TMZ | MX+TMZ | DITC | MX+DITC |
CNSC6SABCBALHPAT | 68%62%58%54%54%60%54% | 64%64%60%64%62%58%56% | 90%96%86%94%98%90%94% | 66%60%56%54%62%62%66% | 98%98%92%84%82%92%98% | 64%64%60%54%52%68%66% | 90%96%86%94%98%90%94% | 66%60%66%64%62%62%66% | 98%98%92%84%82%92%98% |
试验组(n) | 所受治疗 | 肿瘤体积(cm3) | P值 |
1(6) | 对照 | 86.5±33cm3 | |
2(6) | MX | 62±4.3cm3 | <0.05 |
3(6) | ACNU | 54±2.3cm3 | <0.01 |
4(6) | 阿莫司汀 | 46±3.6cm3 | <0.01 |
5(6) | CCNU | 46±3.4cm3 | <0.01 |
6(6) | 雌莫司汀 | 44±3.8cm3 | <0.01 |
7(6) | MX+ACNU | 34±3.6cm3 | <0.001 |
8(6) | MX+阿莫司汀 | 32±3.6cm3 | <0.001 |
9(6) | MX+CCNU | 22±3.6cm3 | <0.001 |
10(6) | MX+雌莫司汀 | 19±3.6cm3 | <0.001 |
试验组(n) | 所受治疗 | 肿瘤体积(cm3) | P值 |
1(6) | 对照 | 90.5±12cm3 | |
2(6) | MX | 50±5.3cm3 | <0.05 |
3(6) | STZ | 61±2.3cm3 | <0.01 |
4(6) | 依莫司汀 | 54±3.4cm3 | <0.01 |
5(6) | TMZ | 48±3.0cm3 | <0.01 |
6(6) | DITC | 44±3.cm3 | <0.01 |
7(6) | MX+STZ | 33±3.0cm3 | <0.001 |
8(6) | MX+依莫司汀 | 32±3.6cm3 | <0.001 |
9(6) | MX+TMZ | 23±3.6cm3 | <0.001 |
10(6) | MX+DITC | 16±3.6cm3 | <0.001 |
试验组(n) | 所受治疗 | 肿瘤体积(cm3) | P值 |
1(6) | 对照 | 86.5±15cm3 | |
2(6) | HX | 51±5.0cm3 | <0.05 |
3(6) | STZ | 60±2.3cm3 | <0.01 |
4(6) | 依莫司汀 | 50±3.4cm3 | <0.01 |
5(6) | TMZ | 46±3.0cm3 | <0.01 |
6(6) | DITC | 42±3.cm3 | <0.01 |
7(6) | HX+STZ | 30±3.0cm3 | <0.001 |
8(6) | 依莫司汀 | 30±3.6cm3 | <0.001 |
9(6) | HX+TMZ | 20±3.6cm3 | <0.001 |
10(6) | HX+DITC | 16±3.6cm3 | <0.001 |
甲基转移酶抑制剂 | 甲基转移酶抑制率(%) |
甲胺甲氧胺二甲胺四环素羟基胺O-羟基胺O-甲基羟基胺O-δ-氨氧丁基羟基胺 | 88908080848088 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410035924 CN1279980C (zh) | 2004-10-14 | 2004-10-14 | 一种抗实体肿瘤药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410035924 CN1279980C (zh) | 2004-10-14 | 2004-10-14 | 一种抗实体肿瘤药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1628850A CN1628850A (zh) | 2005-06-22 |
CN1279980C true CN1279980C (zh) | 2006-10-18 |
Family
ID=34845740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410035924 Expired - Fee Related CN1279980C (zh) | 2004-10-14 | 2004-10-14 | 一种抗实体肿瘤药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1279980C (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100464785C (zh) * | 2005-08-30 | 2009-03-04 | 孔庆忠 | 一种抗癌药物缓释注射剂及其应用 |
US20070197599A1 (en) * | 2006-02-02 | 2007-08-23 | Matier William L | Hydroxylamines and derivatives as anti-angiogenic agents |
CN102370983B (zh) * | 2010-08-10 | 2014-07-23 | 山东新时代药业有限公司 | 一种抗肿瘤药物组合物及其用途 |
WO2016062278A1 (zh) * | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | 内分泌疾病用药在制备抑制癌症的医药组合物中的应用 |
CN115227834A (zh) * | 2022-06-02 | 2022-10-25 | 中国人民解放军海军军医大学 | 通过基因编辑技术联合dna损伤修复抑制剂特异杀伤癌细胞的方法 |
-
2004
- 2004-10-14 CN CN 200410035924 patent/CN1279980C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1628850A (zh) | 2005-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1857221A (zh) | 一种同载铂类化合物及其增效剂的抗癌缓释剂 | |
CN1279980C (zh) | 一种抗实体肿瘤药物组合物 | |
CN1286526C (zh) | 一种抗癌药物组合物 | |
CN1736486A (zh) | 一种抗癌植入剂 | |
CN1299772C (zh) | 一种抗癌药物组合物 | |
CN1634586A (zh) | 一种抗癌药物组合物 | |
CN1875959A (zh) | 一种抗癌药物组合物 | |
CN100340296C (zh) | 一种抗癌体内植入剂 | |
CN100340297C (zh) | 抗癌体内植入剂 | |
CN100350975C (zh) | 抗癌药物组合物 | |
CN1857210A (zh) | 一种同载抗代谢药物及其增效剂的抗癌缓释剂 | |
CN1299773C (zh) | 一种抗癌药物组合物 | |
CN1839843A (zh) | 氟尿嘧啶缓释注射剂 | |
CN1686556A (zh) | 一种含血管抑制剂的抗实体肿瘤药物组合物 | |
CN1679952A (zh) | 一种抗癌药物组合物 | |
CN1679948A (zh) | 抗癌体内植入剂 | |
CN1686546A (zh) | 含血管抑制剂的抗实体肿瘤药物组合物 | |
CN1923283A (zh) | 一种抗癌药物缓释注射剂及其应用 | |
CN1679936A (zh) | 一种抗癌药物组合物 | |
CN1850042A (zh) | 同载铂类药物及其增效剂的抗癌缓释剂 | |
CN1733305A (zh) | 抗癌植入剂 | |
CN1733306A (zh) | 一种含血管抑制剂和鸟嘌呤类似物的抗癌植入剂 | |
CN1923286A (zh) | 一种同载抗癌抗生素及其增效剂的抗癌缓释剂 | |
CN1698592A (zh) | 一种治疗颅外实体肿瘤的药物组合物 | |
CN1733300A (zh) | 一种抗癌植入剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NANJING TIANYI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: KONG QINGZHONG Effective date: 20090904 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090904 Address after: Room 28, building 112, hi tech Industrial Development Zone, Jiangsu, Nanjing Patentee after: Nanjing Tianyi Pharmaceutical Co., Ltd. Address before: Shandong Province, Lixia District of Ji'nan City 2-2 (Yanliu garden) Swallow Hill Road No. 9 Building 2 unit 602 Patentee before: Kong Qingzhong |
|
DD01 | Delivery of document by public notice |
Addressee: Liu Lijun Document name: Notification of Passing Examination on Formalities |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061018 Termination date: 20161014 |
|
CF01 | Termination of patent right due to non-payment of annual fee |